PMID- 20572302
OWN - NLM
STAT- MEDLINE
DCOM- 20100920
LR  - 20211020
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 16
IP  - 24
DP  - 2010 Jun 28
TI  - Emodin enhances alveolar epithelial barrier function in rats with experimental 
      acute pancreatitis.
PG  - 2994-3001
AB  - AIM: To investigate the effect of emodin on expression of claudin-4, claudin-5 
      and occludin, as well as the alveolar epithelial barrier in rats with 
      pancreatitis induced by sodium taurocholate. METHODS: Experimental pancreatitis 
      was induced by retrograde injection of 5% sodium taurocholate into the 
      biliopancreatic duct. Emodin was injected via the external jugular vein 3 h after 
      induction of acute pancreatitis. Rats from sham operation group and acute 
      pancreatitis group were injected with normal saline (an equivalent volume as 
      emodin) at the same time point. Samples of lung and serum were obtained 6 h after 
      drug administration. Pulmonary morphology was examined with HE staining. 
      Pulmonary edema was estimated by measuring water content in lung tissue samples. 
      Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) level were 
      measured by enzyme-linked immunospecific assay. Serum amylase and pulmonary 
      myeloperoxidase (MPO) activity were detected by spectrophotometry. Alveolar 
      epithelial barrier was assessed by pulmonary dye extravasation. Expression of 
      claudin-4, claudin-5 and occludin in lung tissue samples was examined by 
      immunohistology, quantitative real-time reverse transcription polymerase chain 
      reaction and Western blotting analysis, respectively. RESULTS: 
      Pancreatitis-associated lung injury was characterized by pulmonary edema, 
      leukocyte infiltration, alveolar collapse, and elevated serum amylase level. The 
      pulmonary damage, pulmonary pathological scores, serum amylase and MPO activity, 
      TNF-alpha and IL-6 levels, and wet/dry ratio were decreased in rats after 
      treatment with emodin. Immunostaining of claudin-4, claudin-5 and occludin was 
      detected in lung tissue samples from rats in sham operation group, which was 
      distributed in alveolar epithelium, vascular endothelium, and bronchial 
      epithelium, respectively. The mRNA and protein expression levels of claudin-4, 
      claudin-5 and occludin in lung tissue samples were markedly decreased, the 
      expression level of claudin-4, claudin-5 and occluding was increased, and the 
      pulmonary dye extravasation was reduced in lung tissue samples from rats with 
      acute pancreatitis after treatment with emodin. CONCLUSION: Emodin attenuates 
      pulmonary edema and inflammation, enhances alveolar epithelial barrier function, 
      and promotes expression of claudin-4, claudin-5 and occludin in lung tissue 
      samples from rats with acute pancreatitis.
FAU - Xia, Xian-Ming
AU  - Xia XM
AD  - Department of Gastroenterology and Hepatology, Jinling Hospital, Nanjing 210002, 
      Jiangsu Province, China. drxxming@gmail.com
FAU - Wang, Fang-Yu
AU  - Wang FY
FAU - Wang, Zhen-Kai
AU  - Wang ZK
FAU - Wan, Hai-Jun
AU  - Wan HJ
FAU - Xu, Wen-An
AU  - Xu WA
FAU - Lu, Heng
AU  - Lu H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Claudin-4)
RN  - 0 (Claudin-5)
RN  - 0 (Cldn5 protein, rat)
RN  - 0 (Membrane Proteins)
RN  - 0 (Occludin)
RN  - 0 (Ocln protein, rat)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 5E090O0G3Z (Taurocholic Acid)
RN  - KA46RNI6HN (Emodin)
SB  - IM
MH  - Animals
MH  - Blood-Air Barrier/*drug effects/physiology
MH  - Claudin-4
MH  - Claudin-5
MH  - *Emodin/pharmacology/therapeutic use
MH  - Lung/anatomy & histology/drug effects/metabolism/pathology
MH  - Male
MH  - Membrane Proteins/genetics/metabolism
MH  - Occludin
MH  - Pancreatitis/chemically induced/complications/*drug therapy/*pathology
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - *Pulmonary Alveoli/drug effects/physiology
MH  - Pulmonary Edema/drug therapy/etiology/physiopathology
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Taurocholic Acid/pharmacology
PMC - PMC2890939
EDAT- 2010/06/24 06:00
MHDA- 2010/09/21 06:00
PMCR- 2010/06/28
CRDT- 2010/06/24 06:00
PHST- 2010/06/24 06:00 [entrez]
PHST- 2010/06/24 06:00 [pubmed]
PHST- 2010/09/21 06:00 [medline]
PHST- 2010/06/28 00:00 [pmc-release]
AID - 10.3748/wjg.v16.i24.2994 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2010 Jun 28;16(24):2994-3001. doi: 
      10.3748/wjg.v16.i24.2994.